Cardiff Oncology reports Q4 cash $91.7M; 64% ORR for onvansertib plus SOC in RAS-mut mCRC

Cardiff Oncology, Inc.

2024-FY EPS reported -$0.95 revenue$683,000

64% objective response rate (ORR) for 30mg onvansertib + SOC vs 33% control in first-line RAS-mut mCRC trial (CRDF-004).
Raised $40M oversubscribed registered direct offering; cash runway extended into Q1 2027.
Full-year 2024 net cash used $37.7M; operating expenses $49.3M, up $3.4M YoY.
USPTO issued patent for onvansertib + bev in bev-naïve KRAS-mut mCRC, expiring no earlier than 2043.
Additional CRDF-004 clinical data expected in 1H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.